Literature DB >> 33609156

CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.

Aurelian Ungureanu1,2, Magali Le Garff-Tavernier3, Myrto Costopoulos3, Timothée Parratte4, Abdelmalek Brinet4, Hélène Durand4, Claude Gaultier4, Remy Hurstel5, Isabelle Alamome5, François Sellal4, Guido Ahle4.   

Abstract

BACKGROUND: Interleukin 6 (IL-6) is a pleomorphic cytokine that can be found in the cerebrospinal fluid (CSF) in a wide spectrum of inflammatory pathologies of the central nervous system (CNS).
OBJECTIVE: Our aim was to characterize the diagnostic significance of CSF IL-6 among various CNS inflammatory diseases with pseudotumoral lesions (CNSID) and primary CNS lymphoma (PCNSL).
METHODS: We retrospectively analyzed the CSF IL-6 concentrations in 43 consecutive patients with suspected PCNSL. A total of 28 patients were positively diagnosed with PCNSL and 15 with CNSID. We verified the results with CSF IL-10, an established biomarker for PCNSL.
RESULTS: In the PCNSL group, the median CSF IL-6 concentration was 8 pg/ml, interquartile range (IQR) 5-18.5. For the patients with CNSID, the median concentration was 70 pg/ml, IQR 5-1368. A group comparison showed significantly higher CSF IL-6 levels in patients with CNSID than in those with PCNSL (p = 0.032). Moreover, IL-6 was correlated with CSF cell count in the CNSID group (r = 0.56, p = 0.028), but not in the PCNSL group (r = 0.3, p = 0.13). We found significantly higher CSF IL-10 levels in patients with PCNSL than in patients with CNS inflammatory lesions (p < 0.001). DISCUSSION AND
CONCLUSIONS: Our study suggests that CSF IL-6 levels could represent, in addition to CSF IL-10, a useful biomarker in the differential diagnosis of CNSID and suspected PCNSL.
© 2021. Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Cerebrospinal fluid; Inflammation; Interleukin 10; Interleukin 6; Primary central nervous system lymphoma

Mesh:

Substances:

Year:  2021        PMID: 33609156     DOI: 10.1007/s00415-021-10453-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

Review 2.  IL-17 and Th17 Cells.

Authors:  Thomas Korn; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.

Authors:  Yasuo Sasagawa; Takuya Akai; Osamu Tachibana; Hideaki Iizuka
Journal:  J Neurooncol       Date:  2014-09-26       Impact factor: 4.130

4.  The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.

Authors:  Ludovic Nguyen-Them; Myrto Costopoulos; Marie-Laure Tanguy; Caroline Houillier; Sylvain Choquet; Hind Benanni; Rwaida Elias-Shamieh; Marine Armand; Geraldine Faivre; Sylvie Glaisner; Sandra Malak; Jacques Vargaftig; Khê Hoang-Xuan; Guido Ahle; Valérie Touitou; Nathalie Cassoux; Frédéric Davi; Hélène Merle-Béral; Magali Le Garff-Tavernier; Carole Soussain
Journal:  Eur J Cancer       Date:  2016-05-05       Impact factor: 9.162

5.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Authors:  Takashi Sasayama; Satoshi Nakamizo; Masamitsu Nishihara; Atsufumi Kawamura; Hirotomo Tanaka; Katsu Mizukawa; Shigeru Miyake; Masaaki Taniguchi; Kohkichi Hosoda; Eiji Kohmura
Journal:  Neuro Oncol       Date:  2011-12-12       Impact factor: 12.300

Review 6.  How to facilitate early diagnosis of CNS involvement in malignant lymphoma.

Authors:  Agnieszka Korfel; Martha Nowosielski; Javier Pardo-Moreno; Francisco Javier Penalver; Gabriele Buda; Hind Bennani; Myrto Costopoulos; Magali Le Garff-Tavernier; Carole Soussain; Mathias Schmid; Jose Alberto Orfao; Michael Glantz
Journal:  Expert Rev Hematol       Date:  2016-10-21       Impact factor: 2.929

7.  Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein.

Authors:  Y Levy; J C Brouet
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 8.  IL-6 in inflammation, immunity, and disease.

Authors:  Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-04       Impact factor: 10.005

9.  CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma.

Authors:  James L Rubenstein; Valerie S Wong; Cigall Kadoch; Hua-Xin Gao; Ramon Barajas; Lingjing Chen; S Andrew Josephson; Brian Scott; Vanja Douglas; Mekhala Maiti; Lawrence D Kaplan; Patrick A Treseler; Soonmee Cha; Jimmy H Hwang; Paola Cinque; Jason G Cyster; Clifford Lowell
Journal:  Blood       Date:  2013-04-09       Impact factor: 22.113

10.  Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review.

Authors:  Anouk van Westrhenen; Lisanne C A Smidt; Tatjana Seute; Stefan Nierkens; Abraham C J Stork; Monique C Minnema; Tom J Snijders
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

View more
  1 in total

Review 1.  Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Authors:  Aigli G Vakrakou; Maria-Evgenia Brinia; Ioanna Svolaki; Theodore Argyrakos; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.